$LXRX
LEXICON PHARMACEUTICALS, INC.

2011 Q3 Form 10-Q Financial Statement

#000106282211000048 Filed on August 09, 2011

View on sec.gov

Income Statement

Concept 2011 Q3 2011 Q2 2010 Q2
Revenue $355.0K $555.0K $1.233M
YoY Change -54.55% -54.99% -58.9%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.100M $5.400M $5.100M
YoY Change -16.33% 5.88% -8.93%
% of Gross Profit
Research & Development $19.66M $20.15M $20.24M
YoY Change 3.77% -0.46% 0.19%
% of Gross Profit
Depreciation & Amortization $1.200M $1.300M $1.300M
YoY Change -14.29% 0.0% -13.33%
% of Gross Profit
Operating Expenses $26.05M $26.48M $25.31M
YoY Change 4.04% 4.64% -1.91%
Operating Profit -$25.69M -$25.93M -$24.07M
YoY Change 5.93% 7.69%
Interest Expense $560.0K $810.0K $729.0K
YoY Change -12.09% 11.11% -464.5%
% of Operating Profit
Other Income/Expense, Net $88.00K $30.00K -$643.0K
YoY Change -103.26% -104.67% 7.17%
Pretax Income -$26.10M -$26.60M -$25.20M
YoY Change -5.21% 5.56% 7.23%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$26.10M -$26.64M -$25.19M
YoY Change -5.12% 5.74% 25.34%
Net Earnings / Revenue -7352.96% -4799.64% -2043.23%
Basic Earnings Per Share
Diluted Earnings Per Share -$541.5K -$551.9K -$522.8K
COMMON SHARES
Basic Shares Outstanding 337.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2011 Q3 2011 Q2 2010 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $143.7M $164.4M $271.8M
YoY Change -37.79% -39.51% 210.98%
Cash & Equivalents $30.52M $20.33M $247.7M
Short-Term Investments $113.2M $144.1M $24.10M
Other Short-Term Assets $4.337M $3.874M $8.600M
YoY Change 31.42% -54.95% 7.5%
Inventory
Prepaid Expenses
Receivables $489.0K $505.0K $2.100M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $149.0M $169.2M $282.5M
YoY Change -36.77% -40.11% 194.27%
LONG-TERM ASSETS
Property, Plant & Equipment $47.34M $48.37M $56.60M
YoY Change -14.54% -14.54% -7.97%
Goodwill $44.54M $44.54M
YoY Change 0.1%
Intangibles $53.56M $53.56M
YoY Change
Long-Term Investments
YoY Change
Other Assets $281.0K $253.0K $400.0K
YoY Change -43.8% -36.75% -91.3%
Total Long-Term Assets $145.7M $146.7M $82.70M
YoY Change 7.71% 77.42% -44.23%
TOTAL ASSETS
Total Short-Term Assets $149.0M $169.2M $282.5M
Total Long-Term Assets $145.7M $146.7M $82.70M
Total Assets $294.7M $315.9M $365.2M
YoY Change -20.54% -13.5% 49.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.526M $3.671M $3.500M
YoY Change 53.5% 4.89% 9.38%
Accrued Expenses $7.703M $8.037M $6.300M
YoY Change 4.09% 27.57% -8.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.413M $1.380M $17.10M
YoY Change 28.45% -91.93% 1610.0%
Total Short-Term Liabilities $14.81M $13.23M $27.40M
YoY Change 14.78% -51.73% 120.97%
LONG-TERM LIABILITIES
Long-Term Debt $23.83M $24.19M $27.90M
YoY Change -13.67% -13.3% -57.73%
Other Long-Term Liabilities $53.64M $51.36M $14.80M
YoY Change -12.64% 247.01% -0.67%
Total Long-Term Liabilities $77.46M $75.55M $42.70M
YoY Change -12.96% 76.92% -47.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.81M $13.23M $27.40M
Total Long-Term Liabilities $77.46M $75.55M $42.70M
Total Liabilities $125.2M $121.7M $70.10M
YoY Change 22.77% 73.65% -27.88%
SHAREHOLDERS EQUITY
Retained Earnings -$755.8M -$729.7M
YoY Change
Common Stock $338.0K $338.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $345.0K $345.0K
YoY Change
Treasury Stock Shares 218.0K shares 218.0K shares
Shareholders Equity $169.5M $194.2M $295.0M
YoY Change
Total Liabilities & Shareholders Equity $294.7M $315.9M $365.2M
YoY Change -20.54% -13.5% 49.49%

Cashflow Statement

Concept 2011 Q3 2011 Q2 2010 Q2
OPERATING ACTIVITIES
Net Income -$26.10M -$26.64M -$25.19M
YoY Change -5.12% 5.74% 25.34%
Depreciation, Depletion And Amortization $1.200M $1.300M $1.300M
YoY Change -14.29% 0.0% -13.33%
Cash From Operating Activities -$20.20M -$23.70M -$22.60M
YoY Change 8.02% 4.87% -5.44%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$300.0K -$100.0K
YoY Change -33.33% 200.0%
Acquisitions
YoY Change
Other Investing Activities $30.90M $26.80M $30.00M
YoY Change -6280.0% -10.67% -12.02%
Cash From Investing Activities $30.70M $26.50M $30.00M
YoY Change -3937.5% -11.67% -12.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -400.0K -2.600M -19.80M
YoY Change -97.55% -86.87% -189.59%
NET CHANGE
Cash From Operating Activities -20.20M -23.70M -22.60M
Cash From Investing Activities 30.70M 26.50M 30.00M
Cash From Financing Activities -400.0K -2.600M -19.80M
Net Change In Cash 10.10M 200.0K -12.40M
YoY Change -128.21% -101.61% -138.39%
FREE CASH FLOW
Cash From Operating Activities -$20.20M -$23.70M -$22.60M
Capital Expenditures -$200.0K -$300.0K -$100.0K
Free Cash Flow -$20.00M -$23.40M -$22.50M
YoY Change 8.7% 4.0% -5.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2010Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6264000 USD
CY2011Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8037000 USD
CY2011Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
78680000 USD
CY2010Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3159000 USD
CY2011Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3671000 USD
CY2010Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
744000 USD
CY2011Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
505000 USD
CY2010Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
80323000 USD
CY2010Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000 USD
CY2011Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
71000 USD
CY2011Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
923797000 USD
CY2010Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
920324000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2625000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2922000 USD
CY2011Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
35000 USD
CY2010Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
35000 USD
CY2011Q2 us-gaap Assets
Assets
315916000 USD
CY2010Q4 us-gaap Assets
Assets
366884000 USD
CY2010Q4 us-gaap Assets Current
AssetsCurrent
214738000 USD
CY2011Q2 us-gaap Assets Current
AssetsCurrent
169193000 USD
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47208000 USD
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20328000 USD
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100554000 USD
CY2010Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
247698000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-26880000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
147144000 USD
CY2010Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2011Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
562000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
815000 USD
us-gaap Contracts Revenue
ContractsRevenue
2805000 USD
CY2010Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2010Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2011Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2011Q2 us-gaap Common Stock Value
CommonStockValue
338000 USD
CY2010Q4 us-gaap Common Stock Value
CommonStockValue
338000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-56201000 USD
CY2011Q2 us-gaap Contracts Revenue
ContractsRevenue
461000 USD
CY2010Q2 us-gaap Contracts Revenue
ContractsRevenue
1164000 USD
us-gaap Contracts Revenue
ContractsRevenue
977000 USD
CY2010Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
214000 USD
CY2011Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
138000 USD
CY2010Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14212000 USD
CY2011Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
14212000 USD
CY2011Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
18745000 USD
CY2010Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
18745000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2571000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2745000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2010Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2011Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
us-gaap Gain Loss On Investments
GainLossOnInvestments
141000 USD
CY2010Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
53000 USD
us-gaap Gain Loss On Investments
GainLossOnInvestments
0 USD
CY2011Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
10000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
15000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9285000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10587000 USD
CY2010Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5068000 USD
CY2011Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4532000 USD
CY2010Q4 us-gaap Goodwill
Goodwill
44543000 USD
CY2011Q2 us-gaap Goodwill
Goodwill
44543000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
800000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2360000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1459000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
851000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-239000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
76000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
428000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
49000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
366000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3053000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-991000 USD
CY2011Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
53557000 USD
CY2010Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
53557000 USD
CY2011Q2 us-gaap Interest Expense
InterestExpense
810000 USD
CY2010Q2 us-gaap Interest Expense
InterestExpense
729000 USD
us-gaap Interest Expense
InterestExpense
1456000 USD
us-gaap Interest Expense
InterestExpense
1417000 USD
us-gaap Interest Paid Net
InterestPaidNet
1385000 USD
us-gaap Interest Paid Net
InterestPaidNet
1220000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
417000 USD
CY2011Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
68000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
155000 USD
CY2010Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
200000 USD
CY2010Q4 us-gaap Liabilities
Liabilities
119860000 USD
CY2011Q2 us-gaap Liabilities
Liabilities
121728000 USD
CY2010Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
366884000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
29000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2516000 USD
CY2011Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
315916000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44323000 USD
CY2010Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10775000 USD
CY2011Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13226000 USD
CY2011Q2 us-gaap Licenses Revenue
LicensesRevenue
94000 USD
CY2010Q2 us-gaap Licenses Revenue
LicensesRevenue
69000 USD
us-gaap Licenses Revenue
LicensesRevenue
69000 USD
us-gaap Licenses Revenue
LicensesRevenue
174000 USD
CY2010Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1138000 USD
CY2011Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
1380000 USD
CY2010Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
27345000 USD
CY2011Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
24188000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
159400000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2835000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
21184000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
32067000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45229000 USD
CY2010Q2 us-gaap Net Income Loss
NetIncomeLoss
-25193000 USD
us-gaap Net Income Loss
NetIncomeLoss
-56267000 USD
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
-26638000 USD
us-gaap Net Income Loss
NetIncomeLoss
-51263000 USD
us-gaap New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets
NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets
-1456000 USD
us-gaap Operating Expenses
OperatingExpenses
51914000 USD
us-gaap Operating Expenses
OperatingExpenses
56213000 USD
CY2010Q2 us-gaap Operating Expenses
OperatingExpenses
25307000 USD
CY2011Q2 us-gaap Operating Expenses
OperatingExpenses
26481000 USD
CY2010Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-24074000 USD
CY2011Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-25926000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-49040000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-55062000 USD
CY2011Q2 us-gaap Other Assets Current
OtherAssetsCurrent
3874000 USD
CY2010Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2883000 USD
CY2010Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
619000 USD
CY2011Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
253000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
66000 USD
CY2010Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
48783000 USD
CY2011Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
51357000 USD
CY2010Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-643000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1325000 USD
CY2010Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2011Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2010Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
dei Entity Registrant Name
EntityRegistrantName
LEXICON PHARMACEUTICALS, INC./DE
CY2011Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
57000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
108000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
149000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
64126000 USD
CY2011Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2010Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2010Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2010Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2011Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
188000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
181491000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
11377000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
32600000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
83609000 USD
us-gaap Profit Loss
ProfitLoss
-56267000 USD
us-gaap Profit Loss
ProfitLoss
-51263000 USD
CY2011Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
48370000 USD
CY2010Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53427000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2915000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
33319000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41327000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44066000 USD
CY2011Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20145000 USD
CY2010Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20239000 USD
CY2011Q2 us-gaap Restricted Investments
RestrictedInvestments
430000 USD
CY2010Q4 us-gaap Restricted Investments
RestrictedInvestments
430000 USD
CY2011Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-729673000 USD
CY2010Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-673406000 USD
CY2010Q2 us-gaap Revenues
Revenues
1233000 USD
us-gaap Revenues
Revenues
1151000 USD
CY2011Q2 us-gaap Revenues
Revenues
555000 USD
us-gaap Revenues
Revenues
2874000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2625000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2922000 USD
CY2011Q2 us-gaap Short Term Investments
ShortTermInvestments
144486000 USD
CY2010Q4 us-gaap Short Term Investments
ShortTermInvestments
163903000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
181474000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
363000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
188000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000 USD
CY2011Q2 us-gaap Stockholders Equity
StockholdersEquity
194188000 USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
247024000 USD
CY2009Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
163497000 USD
CY2010Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
295035000 USD
CY2011Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
194188000 USD
CY2010Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
247024000 USD
CY2011Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
218000 shares
CY2010Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
158000 shares
CY2011Q2 us-gaap Treasury Stock Value
TreasuryStockValue
345000 USD
CY2010Q4 us-gaap Treasury Stock Value
TreasuryStockValue
237000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-149000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
-108000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
66000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
lxrx Amortization Of Symphony Icon Inc Purchase Option
AmortizationOfSymphonyIconIncPurchaseOption
0 USD
lxrx Amortization Of Symphony Icon Inc Purchase Option
AmortizationOfSymphonyIconIncPurchaseOption
1357000 USD
CY2011Q2 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
1804000 USD
lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
2862000 USD
lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
0 USD
CY2010Q2 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
0 USD
lxrx Deconsolidation Of Symphony Icon Inc
DeconsolidationOfSymphonyIconInc
290000 USD
CY2010Q2 lxrx Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted
SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted
337404000 shares
lxrx Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted
SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted
337598000 shares
CY2011Q2 lxrx Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted
SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted
337668000 shares
lxrx Shares Used In Computing Net Loss Attributable To Lexicon Pharmaceuticals Inc Per Common Share Basic And Diluted
SharesUsedInComputingNetLossAttributableToLexiconPharmaceuticalsIncPerCommonShareBasicAndDiluted
267709000 shares
CY2010Q2 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
511000 USD
lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
1265000 USD
CY2011Q2 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
632000 USD
lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
1010000 USD
lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
1657000 USD
lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
1615000 USD
CY2011Q2 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
818000 USD
CY2010Q2 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
809000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2011
dei Document Period End Date
DocumentPeriodEndDate
2011-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001062822
CY2011Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
337677864 shares
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer

Files In Submission

Name View Source Status
0001062822-11-000048-index-headers.html Edgar Link pending
0001062822-11-000048-index.html Edgar Link pending
0001062822-11-000048.txt Edgar Link pending
0001062822-11-000048-xbrl.zip Edgar Link pending
exh311certificationofprinc.htm Edgar Link pending
exh312certificationofprinc.htm Edgar Link pending
exh321certificationofprinc.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
lxrx-20110630.xml Edgar Link completed
lxrx-20110630.xsd Edgar Link pending
lxrx-20110630_cal.xml Edgar Link unprocessable
lxrx-20110630_def.xml Edgar Link unprocessable
lxrx-20110630_lab.xml Edgar Link unprocessable
lxrx-20110630_pre.xml Edgar Link unprocessable
lxrx630201110-q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending